Lung cancer is a major public health problem worldwide and the leading cause of cancerrelated
mortality in developed countries. Significant advances have been made especially with the
discovery of targeted agents. However, only a small proportion of patients carry activating mutations;
until recently conventional chemotherapy and angiogenesis inhibitors were the preferred treatment for
the vast majority of patients. Now, the successful experience of anti-PD-1 agents may have opened the
door to a novel and previously unexplored dimension in the treatment of lung cancer: immunotherapy.
In this mini-review we will discuss the current applications and future consequences related this topic, paying special
attention to the clinical studies that constitute the scientific evidence to supports its use.
Keywords: Immunotherapy, lung cancer, nivolumab, PD-1, squamous cell carcinoma.
Rights & PermissionsPrintExport